Pharmaceutical company Moderna announces that it is testing a specific vaccine (mRNA-1273.529) against the Omicron variant in addition to its vaccine booster candidates. Against Omicron “we have three lines of defense advancing in parallel: a booster with a higher dose of mRNA-1273 (100 mg). Then, we are studying in the clinical phase two multi-valent booster candidates that anticipate mutations such as those emerged in Omicron. and data is expected for next week. We are also moving forward with a candidate specific booster against Omicron (mRNA-1273.529). ” This was stated by Stéphane Bancel, Moderna’s chief executive officer.
breaking latest news © Copyright ANSA